These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 15154741)

  • 21. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
    Wiseman GA; White CA; Sparks RB; Erwin WD; Podoloff DA; Lamonica D; Bartlett NL; Parker JA; Dunn WL; Spies SM; Belanger R; Witzig TE; Leigh BR
    Crit Rev Oncol Hematol; 2001; 39(1-2):181-94. PubMed ID: 11418315
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma.
    Witzig TE
    Semin Oncol; 2003 Dec; 30(6 Suppl 17):11-6. PubMed ID: 14710398
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study.
    Ibatici A; Pica GM; Nati S; Vitolo U; Botto B; Ciochetto C; Petrini M; Galimberti S; Ciabatti E; Orciuolo E; Zinzani PL; Cascavilla N; Guolo F; Fraternali Orcioni G; Carella AM
    Br J Haematol; 2014 Mar; 164(5):710-6. PubMed ID: 24344981
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma.
    Wiseman GA; White CA; Stabin M; Dunn WL; Erwin W; Dahlbom M; Raubitschek A; Karvelis K; Schultheiss T; Witzig TE; Belanger R; Spies S; Silverman DH; Berlfein JR; Ding E; Grillo-López AJ
    Eur J Nucl Med; 2000 Jul; 27(7):766-77. PubMed ID: 10952488
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody.
    Wagner HN; Wiseman GA; Marcus CS; Nabi HA; Nagle CE; Fink-Bennett DM; Lamonica DM; Conti PS
    J Nucl Med; 2002 Feb; 43(2):267-72. PubMed ID: 11850494
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ongoing trials with yttrium 90-labeled ibritumomab tiuxetan in patients with non-Hodgkin's lymphoma.
    Micallef IN
    Clin Lymphoma; 2004 Oct; 5 Suppl 1():S27-32. PubMed ID: 15498147
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antilymphoma treatments given subsequent to Yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature.
    Ansell SM; Schilder RJ; Pieslor PC; Gordon LI; Emmanouilides C; Vo K; Czuczman MS; Witzig TE; Theuer C; Molina A
    Clin Lymphoma; 2004 Dec; 5(3):202-4. PubMed ID: 15636698
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of ibritumomab tiuxetan radioimmunotherapy for patients with relapsed B-cell non-Hodgkin's lymphoma.
    Witzig TE
    Semin Oncol; 2000 Dec; 27(6 Suppl 12):74-8. PubMed ID: 11226003
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphoma.
    Weigert O; Illidge T; Hiddemann W; Dreyling M
    Cancer; 2006 Aug; 107(4):686-95. PubMed ID: 16826593
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium.
    Hainsworth JD; Spigel DR; Markus TM; Shipley D; Thompson D; Rotman R; Dannaher C; Greco FA
    Clin Lymphoma Myeloma; 2009 Jun; 9(3):223-8. PubMed ID: 19525191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for patients with relapsed CD20+ B-cell non-Hodgkin's lymphoma.
    Alcindor T; Witzig TE
    Curr Treat Options Oncol; 2002 Aug; 3(4):275-82. PubMed ID: 12074764
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma.
    Witzig TE; White CA; Gordon LI; Wiseman GA; Emmanouilides C; Murray JL; Lister J; Multani PS
    J Clin Oncol; 2003 Apr; 21(7):1263-70. PubMed ID: 12663713
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ibritumomab tiuxetan for non-Hodgkin's lymphoma.
    Johnston PB; Bondly C; Micallef IN
    Expert Rev Anticancer Ther; 2006 Jun; 6(6):861-9. PubMed ID: 16761929
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study.
    Cooney-Qualter E; Krailo M; Angiolillo A; Fawwaz RA; Wiseman G; Harrison L; Kohl V; Adamson PC; Ayello J; vande Ven C; Perkins SL; Cairo MS;
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5652s-5660s. PubMed ID: 17875803
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma.
    Tobinai K; Watanabe T; Ogura M; Morishima Y; Hotta T; Ishizawa K; Itoh K; Okamoto S; Taniwaki M; Tsukamoto N; Okumura H; Terauchi T; Nawano S; Matsusako M; Matsuno Y; Nakamura S; Mori S; Ohashi Y; Hayashi M; Endo K
    Cancer Sci; 2009 Jan; 100(1):158-64. PubMed ID: 19018755
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selecting patients for treatment with 90Y ibritumomab tiuxetan (Zevalin).
    Gregory SA
    Semin Oncol; 2003 Dec; 30(6 Suppl 17):17-22. PubMed ID: 14710399
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma.
    Zinzani PL; Tani M; Fanti S; Stefoni V; Musuraca G; Vitolo U; Perrotti A; Fina M; Derenzini E; Baccarani M
    Cancer; 2008 Feb; 112(4):856-62. PubMed ID: 18189293
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma.
    Wiseman GA; Witzig TE
    Cancer Biother Radiopharm; 2005 Apr; 20(2):185-8. PubMed ID: 15869453
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma.
    Krishnan A; Nademanee A; Fung HC; Raubitschek AA; Molina A; Yamauchi D; Rodriguez R; Spielberger RT; Falk P; Palmer JM; Forman SJ
    J Clin Oncol; 2008 Jan; 26(1):90-5. PubMed ID: 18025438
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice.
    Jacene HA; Filice R; Kasecamp W; Wahl RL
    J Nucl Med; 2007 Nov; 48(11):1767-76. PubMed ID: 17942813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.